Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.60 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.60 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.60 |
| ▸ | TOP2A | P11388 | 3/20 | 0.57 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.57 |
| ▸ | GSK3B | P49841 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8558156 | 0.92 | MEN1 (0.61) | MEN1KMT2APOLBKCNH2MAPK1 | |
| SCHEMBL8557677 | 0.91 | MEN1 (0.60) | MEN1KMT2APOLBKCNH2MAPK1 | |
| SCHEMBL10679862 | 0.91 | MEN1 (0.74) | MEN1KMT2APOLBKCNH2MAPK1 | |
| SCHEMBL10412149 | 0.90 | CACNA1F (0.71) | MEN1KMT2APOLBKCNH2MAPK1 | |
| SCHEMBL8852507 | 0.90 | MEN1 (0.59) | MEN1KMT2APOLBKCNH2MAPK1 | |
| SCHEMBL9476701 | 0.89 | MEN1 (0.57) | MEN1KMT2APOLBKCNH2MAPK1 | |
| SCHEMBL8557708 | 0.88 | MEN1 (0.57) | MEN1KMT2APOLBKCNH2MAPK1 | |
| SCHEMBL10679842 | 0.88 | MEN1 (0.65) | MEN1KMT2APOLBKCNH2MAPK1 | |
| SCHEMBL10575715 | 0.88 | MEN1 (0.67) | MEN1KMT2APOLBKCNH2MAPK1 | |
| SCHEMBL10683491 | 0.88 | MEN1 (0.67) | MEN1KMT2APOLBKCNH2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | claimed |
| US-4795751-A | 5-substituted-6,8-difluoroquinolines useful as antibacterial agents | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-01-03 | — | — | US | claimed |
| EP-0284935-A1 | 5-Substituted quinolone- and naphthyridone carboxylic acid derivatives | BAYER AG (DE) | 1988-10-05 | — | — | EP | claimed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | claimed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| EP-1083920-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0525057-B1 | ANTIMICROBIAL QUINOLONYL LACTAMS | PROCTER & GAMBLE PHARMA (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999064051-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5530116-A | Antimicrobial quinolonyl lactams | THE PROCTER & GAMBLE COMPANY (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1991016327-A1 | ANTIMICROBIAL QUINOLONYL LACTAMS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1991-10-31 | — | — | WO | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0375658-A1 | Quinoline derivatives and processes for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1990-06-27 | — | — | EP | disclosed |
| US-4795751-A | 5-substituted-6,8-difluoroquinolines useful as antibacterial agents | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-01-03 | — | — | US | disclosed |
| EP-0284935-A1 | 5-Substituted quinolone- and naphthyridone carboxylic acid derivatives | BAYER AG (DE) | 1988-10-05 | — | — | EP | disclosed |
| EP-0247464-A1 | New quinolone compounds and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0221463-A2 | Quinoline derivatives and processes for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | MEN1 4338/4885KMT2A 3736/4885POLB 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.